3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Active not recruiting
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Conditions
Hodgkin Disease
20
Lymphoma
6
Lymphoma, T-Cell, Peripheral
5
Lymphoma, T-Cell
5
Mycosis Fungoides
4
Lymphoma, T-Cell, Cutaneous
4
Lymphomatoid Papulosis
3
Lymphoma, Large-Cell, Anaplastic
3
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Neoplasms
2
Lymphoma, Primary Cutaneous Anaplastic Large Cell
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Large B-Cell, Diffuse
2
Immunoblastic Lymphadenopathy
2
Hematologic Diseases
2
Enteropathy-Associated T-Cell Lymphoma
2
Squamous Cell Carcinoma of Head and Neck
1
Sezary Syndrome
1
Recurrence
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Mesothelioma, Malignant
1
Melanoma
1
Lymphoma, Extranodal NK-T-Cell
1
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
1
Leukemia, Large Granular Lymphocytic
1
Leukemia
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Rituximab
88
Cyclophosphamide
81
Prednisone
48
Doxorubicin
44
Lenalidomide
37
Vincristine
35
polatuzumab vedotin
29
Magnetic Resonance Spectroscopy
29
Gemcitabine
27
Etoposide
26
Specimen Handling
25
fludarabine
23
Biopsy
21
Oxaliplatin
20
CT-P10
20
glofitamab
17
tafasitamab
15
obinutuzumab
15
ibrutinib
14
zanubrutinib
13
fludarabine phosphate
13
pembrolizumab
12
axicabtagene ciloleucel
12
Immunotherapy, Adoptive
12
Ifosfamide
12
venetoclax
11
deltacortene
11
prednylidene
10
Prednisolone
10
Leukapheresis
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Lymphoma, Large B-Cell, Diffuse
×
Brentuximab Vedotin
×
1 year
×
Clear all
NCT04404283
2026-04-20
ECHELON-3
Seagen Inc.
Phase 3
Active not recruiting
239 enrolled
1 FDA
NCT02734771
2025-08-12
BV mini CHP
University of Rochester
Phase 2
Active not recruiting
24 enrolled